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 Nuclear protein in testis (NUT) midline carcinoma (NMC) is a 
poorly differentiated squamous cell carcinoma that is character-
ized by a balanced translocation between chromosomes 15 and 19 
[t(15;19)(q14;p13.1)]. This genetic aberration results in the fusion 
of the NUT gene on chromosome 15 to the bromodomain contain-
ing 4 (BRD4) gene on chromosome 19. The resultant BRD4-NUT 
fusion oncogene leads to global hypoacetylation and transcriptional 
repression of genes required for differentiation.” Although it was first 
reported in 1991 by Kubonishi et al., awareness of this condition 
remains low and the diagnosis is overlooked initially in a number 
of patients. A 36-year-old man complained of cough and right-sided 
chest pain for 3 weeks before presentation. Imaging studies revealed 
a right hilar mass, and a bronchoscopic biopsy was consistent with an 
aggressive poorly differentiated neoplasm. A combination of cispla-
tin, ifosfamide, and etoposide was administered for two cycles with-
out any improvement. A repeat core biopsy showed focal squamous 
differentiation; and given the clinical presentation along with the his-
tologic features, NMC was considered in the differential diagnosis. 
Immunohistochemical staining for NUT was positive, and dual-color 
break-apart fluorescence in situ hybridization demonstrated BRD4-
NUT rearrangement, thereby confirming a diagnosis of NMC. Our 
patient was subsequently enrolled on a phase 1 clinical trial of a 
novel, orally bioavailable bromodomain and extra terminal inhibitor, 
GSK525762 (NCT01587703). This report illustrates the challenges 
in diagnosing this rare malignancy, and highlights new treatment 
options for these patients.
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ing 4 nuclear protein in testis, Epigenetics, Bromodomain and extra 
terminal inhibitor, Histone deacetylase inhibitors.
(J Thorac Oncol. 2013;8: 1335-1338)
A 36-year-old white man, with no significant medical his-tory, sought medical attention because of a 10-day history 
of cough and right-sided chest pain. He had never smoked 
cigarettes or used illicit drugs. His physical examination 
was remarkable for a temperature of 39°C and rales in the 
right lower chest. He received oral antimicrobial therapy for 
presumed community-acquired pneumonia. After his symp-
toms did not resolve, a chest radiograph was performed 
3 weeks later, demonstrating a mass in the right hilar area. 
A computed tomography scan of the chest revealed sub-
carinal and right supraclavicular lymphadenopathy, along 
with a conglomerate mass measuring 6 × 6cm in the right 
hilar area (Fig. 1A). A transbronchial core biopsy of the 
right hilar mass showed a poorly differentiated neoplasm 
comprising of large epithelioid cells with a small amount 
of cytoplasm, prominent nucleoli, and extensive necrosis 
(Fig. 1B). Immunostains were negative for keratins (AE1/
AE3, CK7, OSCAR, CAM 5.2), epithelial membrane antigen 
(EMA), CD45, S100, CD117, thyroid transcription factor 1, 
placental alkaline phosphatase, octamer-binding transcription 
factor 4, and vascular markers (CD31, CD34, friend leuke-
mia integration-1 transcription factor 1). A testicular ultra-
sound was unremarkable and serum alfa-fetoprotein level was 
elevated (62 ng/ml, normal <6 ng/ml). A clinical diagnosis of 
nonseminomatous primary mediastinal germ cell tumor was 
made, and the patient was started on combination chemother-
apy consisting of etoposide, ifosfamide, and cisplatin.
A computed tomography scan of the chest performed 
after two cycles of therapy showed marked worsening of 
intrathoracic lymphadenopathy and the right hilar mass (Fig. 
2A). Mediastinoscopy-directed biopsy of the right paratra-
cheal lymphadenopathy demonstrated neoplastic epithelioid 
cells with cytologic features similar to the previous biopsy 
(Fig. 2B). The neoplastic cells focally expressed keratin AE1/
AE3 (Fig. 2C), OSCAR, CAM 5.2, CD138, thyroid tran-
scription factor 1, and CD56. Immunostain for anaplastic 
lymphoma kinase was negative, and epidermal growth factor 
receptor sequencing demonstrated a wild-type gene. Given 
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the clinical presentation together with the histopathologic 
features, nuclear protein in testis (NUT) midline carcinoma 
(NMC) was considered. An immunostain for NUT was posi-
tive (Fig. 3A), and dual-color break-apart fluorescence in situ 
hybridization (FISH) demonstrated bromodomain containing 
4 (BRD4)-NUT rearrangement, consistent with a diagnosis of 
NMC (Fig. 3B). The patient received 2000 cGy of radiation 
therapy to the right thorax, and was subsequently enrolled 
on the first dose level of a recently activated phase 1 clinical 
trial of a novel, orally bioavailable bromodomain and extra 
terminal (BET) inhibitor GSK525762 (NCT01587703).1 By 
protocol design of staggered dosing, the patient received a 
lead-in dose, which was followed 1 week later by additional 
doses. Unfortunately, by the second week of the protocol, his 
disease had progressed rapidly, requiring chest tube drainage 
of a large right serosanguineous pleural effusion, and he died 
before continuous daily dosing could be implemented.
An autopsy was performed, which confirmed the diagno-
sis of NMC. The postmortem examination was remarkable for 
massive hilar lymphadenopathy with extension of tumor to the 
surfaces of the mediastinum, pleura, pulmonary hila, right and 
left lung, trachea, thoracic aorta, diaphragm and subcutaneous 
fat, with extrinsic compression and invasion of both airways and 
vasculature. NMC cells were used for the generation of a cell 
line that has proved useful for both in vitro and in vivo studies.
DISCUSSION
NMC is a rare, aggressive, and almost uniformly fatal, 
genetically defined subtype of squamous cell carcinoma. In 
contrast to most squamous cell carcinomas that have a com-
plex karyotype, NMC is characterized by the presence of a 
single reciprocal translocation, t(15;19)(q14;p13.1). This 
genetic aberration usually results in the fusion of the NUT 
gene on chromosome 15q14 to the BET family gene BRD4 on 
chromosome 19p13.1.2 In a minority of cases, NUT is fused to 
the close homologue of BRD4, BRD3, or a gene of unknown 
identity.3
The true incidence of NMC is unknown. Although it 
was initially recognized as occurring almost exclusively in 
young children, recent literature suggests a broad range of 
age presentation, including individuals older than 60 years.4 
Risk factors for the development of this malignancy remain 
unknown. Given the early age at onset and the observation 
that most patients reported with this tumor are nonsmokers, it 
seems that smoking does not play a pathogenic role. In addi-
tion, Epstein-Barr virus and human papilloma virus have not 
FIgUre 1. A, Computed tomography scan of the chest showing a 6 × 6cm mass in the right hilar area and an enlarged 
subcarinal lymph node. B, Pictorial depiction of the typical breakpoint in NUT midline carcinoma. NUT is present on 15q14 
and BRD4 (bromodomain containing 4) on 19p13.1. Scattered neoplastic cells with large hyperchromatic nuclei, prominent 
nucleoli, and scant cytoplasm in a background of extensive necrosis (cell-block preparation, hematoxylin and eosin 40×).
FIgUre 2. A, Computed tomography scan of the chest 2 months later showing an increase in the size of the right hilar mass 
and the subcarinal lymph node. B, Repeat biopsy 2 months later showing sheets of large neoplastic cells with vesicular chro-
matin and prominent nucleoli. Individual tumor cell necrosis and apoptosis is also seen (hematoxylin and eosin 40×). C, The 
neoplastic cells focally express keratin.
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been detected in NMC tumors.5,6 NMC typically arises from 
midline anatomic sites, most commonly the upper aerodiges-
tive tract and the mediastinum. However, other sites of origin 
such as the parotid gland, pancreas, and iliac bone have also 
been reported.7–9
The pathologic findings of NMC are generally consis-
tent with a poorly differentiated carcinoma with focal squa-
mous differentiation. In a retrospective review of 98 poorly 
differentiated carcinomas in children and young adults, 11 
patients (11%) had NUT gene rearrangements by dual-color 
FISH.3 NUT rearrangement at other sites has an incidence of: 
three in 151 primary sinonasal carcinomas (2%),10 one in 148 
poorly differentiated thymic tumors (0.7%),11 and five in 28 
poorly differentiated carcinomas of the upper aerodigestive 
tract (18%).5 A diagnosis of NMC can be confirmed by karyo-
type analysis that shows t(15:19); however, most squamous 
cell cancers are not submitted for karyotypic analysis. The use 
of FISH technique that uses dual-color, break-apart bacterial 
artificial chromosome probes flanking the NUT and BRD4 
loci has led to improved accuracy in diagnosis. However, 
the development of an immunohistochemical stain for NUT 
expression has 100% specificity and 87% sensitivity in detec-
tion of NUT rearrangement outside of the testis, and is consid-
ered the first-line approach to diagnosis of NMC.12
The vast majority of patients with NMC are treated with 
multimodal therapy including surgery, radiation therapy, and 
chemotherapy. Unfortunately, the outcome of most patients 
with NMC remains dismal, with a median overall survival of 
only 6.7 months.4 A wide array of chemotherapeutic agents 
have been tried—including the use of doxorubicin-based reg-
imens—unfortunately, they are not associated with improved 
outcomes. In the largest reported retrospective analysis of 63 
patients with NMC, early radiation therapy and extent of sur-
gery were the only predictors of improved survival. No che-
motherapy regimen was shown to improve survival.4 Although 
there have been some reports of patients with NUT-variant 
NMCs having a longer survival,3 this large analysis failed to 
show such an association.
Recent experiments have shed light on the role of epi-
genetics in the pathogenesis of this disease. Evidence suggests 
a model whereby the BRD4-NUT fusion oncoprotein binds to 
and activates p300, a histone acetyltransferase, and seques-
ters its activity to localized regions of BRD4-NUT–acetyl-
chromatin binding. This leads to a relative paucity of histone 
deacetylase activity elsewhere, and thereby leads to global 
hypoacetylation and inadequate expression of genes required 
for differentiation. Indeed, therapy with histone deacetylase 
inhibitors (HDACi), which restores chromatin acetylation, has 
been shown to induce terminal differentiation of NMC cells in 
vitro.13 Targeting the BRD4-NUT complex with small-mole-
cule BET inhibitors (BETi), which are acetyl-histone mimet-
ics that competitively inhibit bromodomain-acetyl-histone 
binding, have also been shown to induce squamous differ-
entiation of NMC cells.14 One of the members of this class, 
GSK525762, is being tested in a phase 1 clinical trial.1 This 
trial is in the early stages of dose escalation and is actively 
recruiting subjects; however, a discussion regarding its effi-
cacy as a single agent is not possible at this time. As is the case 
with other targeted therapies, it is possible that combination 
therapy with HDACi and BETi will likely be more effective 
than monotherapy for this aggressive disease. The rapid dis-
ease progression that occurred in the patient presented here 
illustrates the difficulty in evaluating novel agents for this dis-
ease and emphasizes the need for clinical trial designs that 
minimize washout periods from prior treatment, and use phar-
macodynamically effective doses as quickly as possible.
In summary, NMC remains an underrecognized aggres-
sive neoplasm that should be considered in the differential 
diagnosis of poorly differentiated carcinoma without glandu-
lar differentiation, involving any organ, without known causes 
such as human papilloma virus or Epstein-Barr virus. The 
recent commercial availability of an immunohistochemical 
test against the NUT protein will make it easier for patholo-
gists to diagnose NMC, once it is clinically suspected. Our 
case report highlights the importance of repeating a core 
biopsy if patients do not respond to chemotherapy directed 
FIgUre 3. A, Nuclear protein in testis immunostain demonstrating a speckled pattern. B, FISH demonstrating BRD4-NUT 
translocation. Shown is dual color bring-together FISH on tumor cell nuclei using red and green probes covering BRD4 and NUT 
genes, respectively. Nuclei with red-green doublets demonstrate fusion of BRD4 and NUT. The nucleus with two red and two 
green signals represent nontumor nuclei containing two normal alleles each of BRD4 and NUT. FISH, fluorescent in situ hybrid-
ization; BRD4, ; NUT, nuclear protein in testis. 
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toward an initial diagnosis. In addition, fostering an interna-
tional collaboration to enroll patients in a timely fashion on 
clinical trials that target the BRD4-NUT fusion oncogene will 
be critical in improving outcomes of NMC patients.
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